Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Association of NFKB1 −94ins/del ATTG promoter polymorphism with susceptibility to and phenotype of Graves' disease

Genes & Immunity volume 8, pages 532–538 (2007)Cite this article

Abstract

Recently, a functional polymorphism in the NFKB1 gene promoter (−94ins/del ATTG) has been identified and associated with chronic inflammatory diseases. The aim of this study was to analyze the association of NFKB1 polymorphism with susceptibility to and phenotype of Graves' disease (GD). The initial case–control association study, performed in a Polish–Warsaw cohort (388 GD patients and 688 controls), was followed by the two replication studies performed in Polish–Gliwice and Japanese–Kurume cohorts (198 GD patients and 194 controls, and 424 GD patients and 222 controls, respectively). The frequency of the −94del ATTG (D) allele was increased in GD compared to controls in Warsaw cohort. This finding was replicated in Gliwice cohort. Combining both Polish–Caucasian cohorts showed that the NFKB1 polymorphism was significantly associated with susceptibility to GD with a codominant mode of inheritance (P=0.00005; OR=1.37 (1.18–1.60)). No association with GD was found in Japanese cohort. However, subgroup analysis in Japanese GD patients revealed a correlation between the NFKB1genotype and the development of ophthalmopathy (P=0.009; OR=1.49 (1.10–2.01)), and the age of disease onset (P=0.009; OR=1.45 (1.09–1.91)). Our results suggest that NFKB1 −94ins/del ATTG polymorphism may be associated with susceptibility to and/or phenotype of GD.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Accession codes

Accessions

GenBank/EMBL/DDBJ

References

  1. Tak PP, Firestein GS . NF-kappaB: a key role in inflammatory diseases. J Clin Invest 2001; 107: 7–11.

    Google Scholar 

  2. Kumar A, Takada Y, Boriek AM, Aggarwal BB . Nuclear factor-kappaB: its role in health and disease. J Mol Med 2004; 82: 434–448.

    Google Scholar 

  3. Courtois G, Gilmore TD . Mutations in the NF-kappaB signaling pathway: implications for human disease. Oncogene 2006; 25: 6831–6843.

    Google Scholar 

  4. Guo D, Li M, Zhang Y, Yang P, Eckenrode S, Hopkins D et al. A functional variant of SUMO4, a new I kappa B alpha modifier, is associated with type 1 diabetes. Nat Genet 2004; 36: 837–841.

    Google Scholar 

  5. Tsurumaru M, Kawasaki E, Ida H, Migita K, Moriuchi A, Fukushima K et al. Evidence for the role of small ubiquitin-like modifier 4 as a general autoimmunity locus in the Japanese population. J Clin Endocrinol Metab 2006; 91: 3138–3143.

    Google Scholar 

  6. Noso S, Ikegami H, Fujisawa T, Kawabata Y, Asano K, Hiromine Y et al. Association of SUMO4, as a candidate gene for IDDM5, with susceptibility to type 1 diabetes in Asian populations. Ann N Y Acad Sci 2006; 1079: 41–46.

    Google Scholar 

  7. Ikegami H, Fujisawa T, Kawabata Y, Noso S, Ogihara T . Genetics of type 1 diabetes: similarities and differences between Asian and Caucasian populations. Ann N Y Acad Sci 2006; 1079: 51–59.

    Google Scholar 

  8. Jennings CE, Owen CJ, Wilson V, Pearce SH . No association of the codon 55 methionine to valine polymorphism in the SUMO4 gene with Graves' disease. Clin Endocrinol (Oxf) 2005; 62: 362–365.

    Google Scholar 

  9. Simmonds MJ, Heward JM, Carr-Smith J, Foxall H, Franklyn JA, Gough SC . Contribution of single nucleotide polymorphisms within FCRL3 and MAP3K7IP2 to the pathogenesis of Graves' disease. J Clin Endocrinol Metab 2006; 91: 1056–1061.

    Google Scholar 

  10. Smyth DJ, Howson JM, Lowe CE, Walker NM, Lam AC, Nutland S et al. Assessing the validity of the association between the SUMO4 M55V variant and risk of type 1 diabetes. Nat Genet 2005; 37: 110–111.

    Google Scholar 

  11. Karban AS, Okazaki T, Panhuysen CI, Gallegos T, Potter JJ, Bailey-Wilson JE et al. Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet 2004; 13: 35–45.

    Google Scholar 

  12. Borm ME, van Bodegraven AA, Mulder CJ, Kraal G, Bouma G . A NFKB1 promoter polymorphism is involved in susceptibility to ulcerative colitis. Int J Immunogenet 2005; 32: 401–405.

    Google Scholar 

  13. Glas J, Torok HP, Tonenchi L, Muller-Myhsok B, Mussack T, Wetzke M et al. Role of the NFKB1 -94ins/del ATTG promoter polymorphism in IBD and potential interactions with polymorphisms in the CARD15/NOD2, IKBL, and IL-1RN genes. Inflamm Bowel Dis 2006; 12: 606–611.

    Google Scholar 

  14. Mirza MM, Fisher SA, Onnie C, Lewis CM, Mathew CG, Sanderson J et al. No association of the NFKB1 promoter polymorphism with ulcerative colitis in a British case control cohort. Gut 2005; 54: 1205–1206.

    Google Scholar 

  15. Oliver J, Gomez-Garcia M, Paco L, Lopez-Nevot MA, Pinero A, Correro F et al. A functional polymorphism of the NFKB1 promoter is not associated with ulcerative colitis in a Spanish population. Inflamm Bowel Dis 2005; 11: 576–579.

    Google Scholar 

  16. Orozco G, Sanchez E, Collado MD, Lopez-Nevot MA, Paco L, Garcia A et al. Analysis of the functional NFKB1 promoter polymorphism in rheumatoid arthritis and systemic lupus erythematosus. Tissue Antigens 2005; 65: 183–186.

    Google Scholar 

  17. Rueda B, Nunez C, Lopez-Nevot MA, Paz Ruiz M, Urcelay E, De la Concha EG et al. Functional polymorphism of the NFKB1 gene promoter is not relevant in predisposition to celiac disease. Scand J Gastroenterol 2006; 41: 420–423.

    Google Scholar 

  18. Kosoy R, Concannon P . Functional variants in SUMO4, TAB2, and NFkappaB and the risk of type 1 diabetes. Genes Immun 2005; 6: 231–235.

    Google Scholar 

  19. Martinez A, Sanchez E, Valdivia A, Orozco G, Lopez-Nevot MA, Pascual-Salcedo D et al. Epistatic interaction between FCRL3 and NFkappaB1 genes. Ann Rheum Dis 2006; 65: 1188–1191.

    Google Scholar 

  20. Kochi Y, Yamada R, Suzuki A, Harley JB, Shirasawa S, Sawada T et al. A functional variant in FCRL3, encoding Fc receptor-like 3, is associated with rheumatoid arthritis and several autoimmunities. Nat Genet 2005; 37: 478–485.

    Google Scholar 

  21. Hegazy DM, O'Reilly DA, Yang BM, Hodgkinson AD, Millward BA, Demaine AG . NFkappaB polymorphisms and susceptibility to type 1 diabetes. Genes Immun 2001; 2: 304–308.

    Google Scholar 

  22. Gylvin T, Bergholdt R, Nerup J, Pociot F . Characterization of a nuclear-factor-kappa B (NFkappaB) genetic marker in type 1 diabetes (T1DM) families. Genes Immun 2002; 3: 430–432.

    Google Scholar 

  23. Smyth DJ, Howson JM, Payne F, Maier LM, Bailey R, Holland K et al. Analysis of polymorphisms in 16 genes in type 1 diabetes that have been associated with other immune-mediated diseases. BMC Med Genet 2006; 7: 20.

    Google Scholar 

  24. Hiromatsu Y, Yang D, Bednarczuk T, Miyake I, Nonaka K, Inoue Y . Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 2000; 85: 1194–1199.

    Google Scholar 

  25. Ajjan RA, Weetman AP . New understanding of the role of cytokines in the pathogenesis of Graves'ophthalmopathy. J Endocrinol Invest 2004; 27: 237–245.

    Google Scholar 

  26. Cao HJ, Smith TJ . Leukoregulin upregulation of prostaglandin endoperoxide H synthase-2 expression in human orbital fibroblasts. Am J Physiol 1999; 277: C1075–C1085.

    Google Scholar 

  27. De Bosscher K, Vanden Berghe W, Haegeman G . The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr Rev 2003; 24: 488–522.

    Google Scholar 

  28. Garrity JA, Bahn RS . Pathogenesis of Graves' ophthalmopathy: implications for prediction, prevention,and treatment. Am J Ophthalmol 2006; 142: 147–153.

    Google Scholar 

  29. Manji N, Carr-Smith JD, Boelaert K, Allahabadia A, Armitage M, Chatterjee VK et al. Influences of age, gender, smoking, and family history on autoimmune thyroid disease phenotype. J Clin Endocrinol Metab 2006; 91: 4873–4880.

    Google Scholar 

  30. Bednarczuk T, Hiromatsu Y, Fukutani T, Jazdzewski K, Miskiewicz P, Osikowska M et al. Association of cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) gene polymorphism and non-genetic factors with Graves' ophthalmopathy in European and Japanese populations. Eur J Endocrinol 2003; 48: 13–18.

    Google Scholar 

  31. Johnson GC, Esposito L, Barratt BJ, Smith AN, Heward J, Di Genova G et al. Haplotype tagging for the identification of common disease genes. Nat Genet 2001; 29: 233–237.

    Google Scholar 

  32. Kavvoura FK, Akamizu T, Awata T, Ban Y, Chistiakov DA, Frydecka I et al. CTLA-4 gene polymorphisms and autoimmune thyroid disease: a meta analysis. J Clin Endocrinol Metab (in press).

  33. Kula D, Bednarczuk T, Jurecka-Lubieniecka B, Polanska J, Hasse-Lazar K, Jarzab M et al. Interaction of HLA-DRB1 alleles with CTLA-4 in the predisposition to Graves' disease: The impact of DRB1*07. Thyroid 2006; 16: 447–453.

    Google Scholar 

  34. Perneger TV . What's wrong with Bonferroni adjustment? BMJ 1998; 316: 1236–1238.

    Google Scholar 

  35. Hosmer D, Lemeshow S . Applied Logistic Regression, 2nd edn. Wiley Interscience: New York, 2000, pp 70–79.

    Google Scholar 

Download references

Acknowledgements

This work was supported by the State Committee for Scientific Research Grants No. 2 PO5B 120 29, 3 T11F 010 29 and the Medical University of Warsaw Grant 1WY/N/2007.

Author information

Authors and Affiliations

  1. Department of Endocrinology, Medical Research Center, Polish Academy of Science, Warsaw, Poland

    A Kurylowicz, J Nauman & T Bednarczuk

  2. Department of Endocrinology, Kurume University School of Medicine, Fukuoka, Japan

    Y Hiromatsu, M Ichimura, H Koga & H Kaku

  3. Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland

    B Jurecka-Lubieniecka, D Kula, M Kowalska & B Jarzab

  4. Department of Endocrinology, Medical University of Warsaw, Warsaw, Poland

    E Bar-Andziak & T Bednarczuk

  5. Department of Medical Genetics, Medical University of Warsaw, Warsaw, Poland

    R Ploski

Authors
  1. A Kurylowicz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Y Hiromatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B Jurecka-Lubieniecka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D Kula
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Kowalska
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Ichimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H Koga
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. H Kaku
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. E Bar-Andziak
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J Nauman
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. B Jarzab
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. R Ploski
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. T Bednarczuk
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T Bednarczuk.

Additional information

Disclosure summary

None.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kurylowicz, A., Hiromatsu, Y., Jurecka-Lubieniecka, B. et al. Association of NFKB1 −94ins/del ATTG promoter polymorphism with susceptibility to and phenotype of Graves' disease. Genes Immun 8, 532–538 (2007). https://doi.org/10.1038/sj.gene.6364418

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gene.6364418

Keywords

This article is cited by

Search

Advanced search

Quick links